Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Long Term DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abivax (ABVX) Cash & Equivalents: 2021-2025

Historic Cash & Equivalents for Abivax (ABVX) over the last 1 years, with Jun 2025 value amounting to $69.0 million.

  • Abivax's Cash & Equivalents fell 71.18% to $69.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was $69.0 million, marking a year-over-year decrease of 71.18%. This contributed to the annual value of $154.1 million for FY2024, which is 43.15% down from last year.
  • Per Abivax's latest filing, its Cash & Equivalents stood at $69.0 million for Q2 2025, which was down 36.68% from $108.9 million recorded in Q1 2025.
  • Over the past 5 years, Abivax's Cash & Equivalents peaked at $271.1 million during Q4 2023, and registered a low of $27.5 million during Q4 2022.
  • For the 3-year period, Abivax's Cash & Equivalents averaged around $184.2 million, with its median value being $196.8 million (2024).
  • In the last 5 years, Abivax's Cash & Equivalents surged by 885.88% in 2023 and then crashed by 71.18% in 2025.
  • Abivax's Cash & Equivalents (Quarterly) stood at $69.4 million in 2021, then tumbled by 60.40% to $27.5 million in 2022, then surged by 885.88% to $271.1 million in 2023, then crashed by 43.15% to $154.1 million in 2024, then crashed by 71.18% to $69.0 million in 2025.
  • Its last three reported values are $69.0 million in Q2 2025, $108.9 million for Q1 2025, and $154.1 million during Q4 2024.